128 related articles for article (PubMed ID: 35173819)
1. Adverse events induced by nivolumab and ipilimumab combination regimens.
Somekawa K; Horita N; Kaneko A; Tagami Y; Fukuda N; Matsumoto H; Namkoong H; Fujiwara Y; Minegishi K; Fukumoto T; Watanabe K; Hara Y; Kobayashi N; Kaneko T
Ther Adv Med Oncol; 2022; 14():17588359211058393. PubMed ID: 35173819
[TBL] [Abstract][Full Text] [Related]
2. The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases.
Fukumoto T; Horita N
Transl Oncol; 2022 Aug; 22():101449. PubMed ID: 35598383
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis.
Xu H; Tan P; Ai J; Zhang S; Zheng X; Liao X; Yang L; Wei Q
Front Pharmacol; 2019; 10():1300. PubMed ID: 31749704
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis.
Chen J; Li S; Yao Q; Du N; Fu X; Lou Y; Wang M; Mao F; Mao D; Khadaroo PA; Tang Y
World J Surg Oncol; 2020 Jul; 18(1):150. PubMed ID: 32620130
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis.
Xu Y; Hezam K; Ali MG; Wang Y; Zhang J
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):386-394. PubMed ID: 34014122
[No Abstract] [Full Text] [Related]
7. Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Matsumoto H; Somekawa K; Horita N; Ueda S; Kaneko M; Kaneko A; Fukuda N; Izawa A; Kamimaki C; Tanaka K; Murohashi K; Fuji H; Tagami Y; Aoki A; Watanabe K; Hara Y; Kobayashi N; Kaneko T
Ther Adv Med Oncol; 2023; 15():17588359231198453. PubMed ID: 37720498
[TBL] [Abstract][Full Text] [Related]
8. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
9. Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.
Zhao X; Gao F; Yang J; Fan H; Xie Q; Jiang K; Gong J; Gao B; Yang Q; Lei Z
Front Oncol; 2022; 12():877434. PubMed ID: 35814436
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis.
Zhu Y; Cheng H; Zhong M; Hu Y; Li Q; Gao X; Liu S
J Cancer Res Ther; 2021 Dec; 17(7):1679-1688. PubMed ID: 35381739
[TBL] [Abstract][Full Text] [Related]
11. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
[TBL] [Abstract][Full Text] [Related]
12. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
17. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
18. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
20. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients.
Zhou S; Khanal S; Zhang H
Ther Clin Risk Manag; 2019; 15():211-221. PubMed ID: 30774357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
